NDC 70069-141
Cisatracurium Besylate 2 mg per 1 mL injection
On the label: Somerset Therapeutics, LLC.
Where it's made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| Somerset Therapeutics Private Limited | Bengaluru, India | Makes it, tests it, packages it and labels it | Serious problems, FDA actionFeb 21, 2025 · 10 inspections, 4 with FDA action |
Recalls
- Nov 26, 2025 · Class III · Somerset Therapeutics Llc
Subpotent product:out of specification assay results observed during long term stability testing.
Lots: Lot#: A240438, Exp Date 1/31/26, A250125, Exp Date 8/31/26 - Nov 26, 2025 · Class III · Somerset Therapeutics Llc
Subpotent product:out of specification assay results observed during long term stability testing.
Lots: Lot #: A250020, Exp Date 06/30/2026
Class I recalls are the most serious; Class III the least. A recall covers specific lots, listed on each recall.
Product details
- Generic drug
- Cisatracurium: every company that makes it
- Form
- injection, intravenous
- Strength
- 2 mg per 1 mL
- Approval
- ANDA ANDA206791
- On the market since
- Feb 4, 2019
- Package NDCs
70069-141-0170069-141-10- Official label
- DailyMed (National Library of Medicine), updated Apr 29, 2026
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?